Compare GCBC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | ACHV |
|---|---|---|
| Founded | 1889 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.0M | 618.0M |
| IPO Year | 1998 | 2018 |
| Metric | GCBC | ACHV |
|---|---|---|
| Price | $34.61 | $8.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 25.0K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 26.21 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.93 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $21.25 | $2.62 |
| 52 Week High | $36.02 | $8.61 |
| Indicator | GCBC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 71.63 |
| Support Level | $33.64 | $3.99 |
| Resistance Level | $35.78 | $8.61 |
| Average True Range (ATR) | 0.81 | 0.40 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 47.88 | 86.67 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.